The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...
In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...
The American Heart Association and the American Stroke Association issued guidelines Monday that also look at the effects of testosterone and estrogen on the body. Meanwhile, Eli Lilly sues three ...